FindTrial
Sign In

A Long-Term Clinical Study of TS-071 as Combination Therapy With Glimepiride in Patients With Type 2 Diabetes Mellitus

A Long-Term Clinical Study of TS-071 as Combination Therapy With Glimepiride in Patients With Type 2 Diabetes Mellitus

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221468
Enrollment
225
Registered
2011-05-31
Start date
2011-05-31
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

investigational material(s) Generic name etc : TS-071 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : Or

Sponsors

Taisho Pharmaceutical co., LTD
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Type 2 diabetes mellitus - Has been receiving treatment with glimepiride monotherapy at a fixed dose within the limit of approved continuously for more than 8 weeks. etc.

Exclusion criteria

Exclusion criteria: - Having non-type 2 diabetes mellitus . - Having critical Heart Disease, other ciruculatory disease, cerebrovascular disorder, pancreatic disease and hematologic disease. etc.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026